BioNTech Q2 2026: Revenue Falls 59% on Weak COVID Demand, Oncology Pipeline Advances

BioNTech reported Q2 2026 revenue of €105.6M, down 59% from €260.8M a year earlier, with a net loss of €820.8M (adjusted net loss €562.3M), driven by softening global COVID-19 vaccine demand and an EMA recommendation letting the EU use prior-year vaccine formulas — cutting sales in Germany specifically. The company lowered full-year 2026 revenue guidance to €1.6–1.9B (from €2.0–2.3B) while maintaining €16.6B in cash and securities. On the oncology side, BioNTech highlighted 17+ late-stage/pivotal trials planned through 2030, including four registrational programs for its PD-L1×VEGF-A bispecific pumitamig (BNT327) in lung cancer; ROSETTA Lung-02 Phase 2 data presented at ASCO 2026 showed robust responses across PD-L1 expression levels, including a 47.6% confirmed objective response rate in PD-L1-negative first-line NSCLC patients. The results follow Monday's announcement that Guido Oelkers will succeed Ugur Sahin as CEO.